Stock Ratings / Health Care / FLNA / forecast

AARD (37) IXHL (39) IBO (34) ACET (36) ⌘ Pro Terminal →

Filana Therapeutics Inc. (FLNA) 12-Month Stock Forecast & Price Target Cone

$0.66 +1.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.66

Filana Therapeutics Inc. (FLNA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $31.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.66 (+0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FLNA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY FLNA SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.82-14.6% Next Q

Q2 (-2Q)

Grade C-$0.70-8.6% Next Q

Q3 (-1Q)

Grade C-$0.64+3.1% Next Q

Current

Grade D$0.66-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FLNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FLNA currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.69) forces dealer call-delta covering toward $3.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FLNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FLNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your FLNA Position Size: $10,000

Shares at $0.66: 15151.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.49

$7,424

$-2,576 (-25.8%)

12M Consensus BaseTarget $0.63

$9,545

$-455 (-4.5%)

12M Bull Case BreakoutTarget $3.62

$54,848

+$44,848 (+448.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FLNA)

✓Walkthrough of FLNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FLNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.48%▼ DESCENDING CHANNEL

2026-10-30O $0.66H $0.66L $0.62C $0.66VOL 215.1K

RES: $1.19SUP: $0.49SMA50: $0.79SMA200: $1.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FLNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FLNA Butterfly Map → + Track FLNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FLNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FLNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FLNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FLNA)

Health Care Rank #421 of 1016 ⚔️ AARD vs FLNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FLNA vs. AARD, IXHL, IBO, ACET)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Filana Therapeutics Inc. (FLNA) ranks #421 by composite RQD confidence (47/100, grade D) and #797 by equity capitalization ($31.8M). Within this direct 5-issuer industry benchmark cohort, FLNA leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. FLNA currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FLNA ACTIVE Filana Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.12%	$31.8M	Benchmark Subject
AARD Aardvark Therapeutics Inc.	D-	37/100	—	—	-35.0%	-4.64%	$31.5M	/aard-vs-flna →
IXHL Incannex Healthcare Inc.	D-	39/100	—	—	-35.0%	-4.80%	$32.4M	/ixhl-vs-flna →
IBO Impact BioMedical Inc.	E	34/100	—	-30.0%	-27.5%	-3.00%	$33.1M	/ibo-vs-flna →
ACET Adicet Bio Inc.	D-	36/100	—	—	-35.0%	-6.04%	$33.5M	/acet-vs-flna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001069530

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Filana Therapeutics Inc. (FLNA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$91.0M, operating cash flow of -$32.3M, and free cash flow of -$32.8M (+71.9% YoY). On the balance sheet, FLNA closed FY2025 with $118.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$91.0M	-$32.3M	-$32.8M	$118.4M	—
FY2024 (FY)	2024-12-31	$0	-$24.3M	-$116.9M	-$117.0M	$157.5M	—
FY2023 (FY)	2023-12-31	$0	-$97.2M	-$82.0M	-$82.0M	—	—

3. FLNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FLNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Filana Therapeutics Inc. (NASDAQ: FLNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.66 (+1.12% 1D, market cap $31.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FLNA ranks #421 in composite RQD confidence.

How does FLNA compare to AARD and IXHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FLNA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AARD (Aardvark Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $31.5M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, FLNA leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FLNA?

Per FLNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001069530), Filana Therapeutics Inc. generated $0 in revenue, -$91.0M in net income, and -$32.8M in free cash flow against $118.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FLNA trading relative to its 50-day, 200-day, and 52-week technical levels?

FLNA last traded at $0.66 (+1.12% on volume of 265,174 shares), positioning the stock -16.46% below its 50-day simple moving average ($0.79) and -51.47% below its 200-day simple moving average ($1.36). Across its 52-week range of $0.60 to $3.45, FLNA sits at the 2.1% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).

FLNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is FLNA's 12-month stock price target?

Filana Therapeutics Inc. (FLNA) carries a 12-month consensus base price target of $0.63 (-4.5% from $0.66), with a bull-case target of $3.62 and a bear-case floor of $0.49.

Is FLNA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates FLNA D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: FLNA RQD Cockpit FLNA 12M Forecast FLNA Earnings & Move FLNA Dividends & DRIP FLNA Insiders & 13F FLNA Whale Options FLNA Profit Sankey FLNA News & Why